TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

BACKGROUND: TRK inhibitors achieve marked tumor-agnostic efficacy in TRK fusion-positive cancers and consequently are now an established standard of care. Little is known, however, about the demographics, outcomes, response to alternative standard therapies, or genomic characteristics of TRK fusion-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Rosen, Ezra Y., Goldman, Debra A., Hechtman, Jaclyn F., Benayed, Ryma, Schram, Alison M, Cocco, Emiliano, Shifman, Sophie, Gong, Yixiao, Kundra, Ritika, Solomon, James P., Bardelli, Alberto, Scaltriti, Maurizio, Drilon, Alexander, Iasonos, Alexia, Taylor, Barry S., Hyman, David M.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7124988/
https://ncbi.nlm.nih.gov/pubmed/31871300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3165
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars